Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States

Detalhes bibliográficos
Autor(a) principal: Pan,Kevin
Data de Publicação: 2020
Outros Autores: Silver,Shawgi, Davis,Charles
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Trends in Psychiatry and Psychotherapy
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-60892020000100048
Resumo: Abstract Introduction The opioid epidemic is a severe problem in the world, especially in the United States, where prescription opioid overdose accounts for a quarter of drug overdose deaths. Objective To describe psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in the United States. Methods We conducted a retrospective cross-sectional study of the 2016 Medicare Part D claims data and analyzed psychiatrists’ prescriptions of: 1) opioids; 2) benzodiazepines, whose concurrent prescription with opioids can cause overdose death; 3) buprenorphine, a partial opioid agonist for treating opioid addiction; 4) and naltrexone microsphere, a once-monthly injectable opioid antagonist to prevent relapse to opioid dependence. Prescribers with 11 or more claims were included in the analysis. Results In Medicare Part D in 2016, there were a total of 1,131,550 prescribers accounting for 1,480,972,766 total prescriptions and 78,145,305 opioid prescriptions, including 25,528 psychiatrists (2.6% of all prescribers) accounting for 44,684,504 total prescriptions (3.0% of all prescriptions) and 131,115 opioid prescriptions (0.2% of all opioid prescriptions). Psychiatrists accounted for 17.3% of benzodiazepine, 16.3% of buprenorphine, and 33.4% of naltrexone microsphere prescriptions. The opioid prescription rate of psychiatrists was much lower than that of all prescribers (0.3 vs 5.3%). The buprenorphine prescription rate of psychiatrists was much higher than that of all prescribers (2.3 vs. 0.1%). There was a substantial geographical variation across the United States. Conclusions The results show that, proportionally, psychiatrists have lower rates of opioid prescription and higher rates of benzodiazepine and buprenorphine prescription.
id APRGS-1_20f015ffbf954afda63007cc02fa7b1f
oai_identifier_str oai:scielo:S2237-60892020000100048
network_acronym_str APRGS-1
network_name_str Trends in Psychiatry and Psychotherapy
repository_id_str
spelling Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United StatesPsychiatryaddictiongeriatric psychiatryopioidaddiction treatmentAbstract Introduction The opioid epidemic is a severe problem in the world, especially in the United States, where prescription opioid overdose accounts for a quarter of drug overdose deaths. Objective To describe psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in the United States. Methods We conducted a retrospective cross-sectional study of the 2016 Medicare Part D claims data and analyzed psychiatrists’ prescriptions of: 1) opioids; 2) benzodiazepines, whose concurrent prescription with opioids can cause overdose death; 3) buprenorphine, a partial opioid agonist for treating opioid addiction; 4) and naltrexone microsphere, a once-monthly injectable opioid antagonist to prevent relapse to opioid dependence. Prescribers with 11 or more claims were included in the analysis. Results In Medicare Part D in 2016, there were a total of 1,131,550 prescribers accounting for 1,480,972,766 total prescriptions and 78,145,305 opioid prescriptions, including 25,528 psychiatrists (2.6% of all prescribers) accounting for 44,684,504 total prescriptions (3.0% of all prescriptions) and 131,115 opioid prescriptions (0.2% of all opioid prescriptions). Psychiatrists accounted for 17.3% of benzodiazepine, 16.3% of buprenorphine, and 33.4% of naltrexone microsphere prescriptions. The opioid prescription rate of psychiatrists was much lower than that of all prescribers (0.3 vs 5.3%). The buprenorphine prescription rate of psychiatrists was much higher than that of all prescribers (2.3 vs. 0.1%). There was a substantial geographical variation across the United States. Conclusions The results show that, proportionally, psychiatrists have lower rates of opioid prescription and higher rates of benzodiazepine and buprenorphine prescription.Associação de Psiquiatria do Rio Grande do Sul2020-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-60892020000100048Trends in Psychiatry and Psychotherapy v.42 n.1 2020reponame:Trends in Psychiatry and Psychotherapyinstname:Sociedade de Psiquiatria do Rio Grande do Sulinstacron:APRGS10.1590/2237-6089-2019-0015info:eu-repo/semantics/openAccessPan,KevinSilver,ShawgiDavis,Charleseng2020-05-14T00:00:00Zoai:scielo:S2237-60892020000100048Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=2237-6089&lng=en&nrm=isohttps://old.scielo.br/oai/scielo-oai.phprevista@aprs.org.br|| rodrigo_grassi@terra.com.br2238-00192237-6089opendoar:2020-05-14T00:00Trends in Psychiatry and Psychotherapy - Sociedade de Psiquiatria do Rio Grande do Sulfalse
dc.title.none.fl_str_mv Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
title Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
spellingShingle Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
Pan,Kevin
Psychiatry
addiction
geriatric psychiatry
opioid
addiction treatment
title_short Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
title_full Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
title_fullStr Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
title_full_unstemmed Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
title_sort Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
author Pan,Kevin
author_facet Pan,Kevin
Silver,Shawgi
Davis,Charles
author_role author
author2 Silver,Shawgi
Davis,Charles
author2_role author
author
dc.contributor.author.fl_str_mv Pan,Kevin
Silver,Shawgi
Davis,Charles
dc.subject.por.fl_str_mv Psychiatry
addiction
geriatric psychiatry
opioid
addiction treatment
topic Psychiatry
addiction
geriatric psychiatry
opioid
addiction treatment
description Abstract Introduction The opioid epidemic is a severe problem in the world, especially in the United States, where prescription opioid overdose accounts for a quarter of drug overdose deaths. Objective To describe psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in the United States. Methods We conducted a retrospective cross-sectional study of the 2016 Medicare Part D claims data and analyzed psychiatrists’ prescriptions of: 1) opioids; 2) benzodiazepines, whose concurrent prescription with opioids can cause overdose death; 3) buprenorphine, a partial opioid agonist for treating opioid addiction; 4) and naltrexone microsphere, a once-monthly injectable opioid antagonist to prevent relapse to opioid dependence. Prescribers with 11 or more claims were included in the analysis. Results In Medicare Part D in 2016, there were a total of 1,131,550 prescribers accounting for 1,480,972,766 total prescriptions and 78,145,305 opioid prescriptions, including 25,528 psychiatrists (2.6% of all prescribers) accounting for 44,684,504 total prescriptions (3.0% of all prescriptions) and 131,115 opioid prescriptions (0.2% of all opioid prescriptions). Psychiatrists accounted for 17.3% of benzodiazepine, 16.3% of buprenorphine, and 33.4% of naltrexone microsphere prescriptions. The opioid prescription rate of psychiatrists was much lower than that of all prescribers (0.3 vs 5.3%). The buprenorphine prescription rate of psychiatrists was much higher than that of all prescribers (2.3 vs. 0.1%). There was a substantial geographical variation across the United States. Conclusions The results show that, proportionally, psychiatrists have lower rates of opioid prescription and higher rates of benzodiazepine and buprenorphine prescription.
publishDate 2020
dc.date.none.fl_str_mv 2020-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-60892020000100048
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-60892020000100048
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/2237-6089-2019-0015
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação de Psiquiatria do Rio Grande do Sul
publisher.none.fl_str_mv Associação de Psiquiatria do Rio Grande do Sul
dc.source.none.fl_str_mv Trends in Psychiatry and Psychotherapy v.42 n.1 2020
reponame:Trends in Psychiatry and Psychotherapy
instname:Sociedade de Psiquiatria do Rio Grande do Sul
instacron:APRGS
instname_str Sociedade de Psiquiatria do Rio Grande do Sul
instacron_str APRGS
institution APRGS
reponame_str Trends in Psychiatry and Psychotherapy
collection Trends in Psychiatry and Psychotherapy
repository.name.fl_str_mv Trends in Psychiatry and Psychotherapy - Sociedade de Psiquiatria do Rio Grande do Sul
repository.mail.fl_str_mv revista@aprs.org.br|| rodrigo_grassi@terra.com.br
_version_ 1754209281566048256